Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

ONTX was reduced by Zacks  from a “get” ranking to a “hold” ranking in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on uncovering and creating small particle medication prospects to deal with cancer. The Business‘s products under different phases of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts additionally just recently commented on the company. Noble Financial reissued a “acquire” rating and also released a $11.00 rate purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and established a “acquire” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving average cost of $2.90 as well as a two-hundred day relocating typical price of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, topping analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as an adverse internet margin of 8,294.27%. The company had income of $0.06 million during the quarter, contrasted to the agreement quote of $0.06 million. Throughout the exact same quarter in the previous year, the company published ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will upload -1.18 EPS for the existing year.

A variety of hedge funds have actually lately dealt shares of ONTX. GSA Resources Allies LLP got a new setting in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Administration LP purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional capitalists own 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the identification as well as growth of oncology therapeutics. It focuses on uncovering and establishing little molecule medication prospects to deal with cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a complimentary copy of the Zacks research report on Onconova Therapeutics (ONTX).

For more details about research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate news alert was created by narrative science modern technology as well as monetary information from Market in order to provide visitors with the fastest as well as most precise reporting. This tale was reviewed by Market’s editorial group prior to publication. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Prior to you think about Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s top-rated and also ideal doing research experts and the stocks they recommend to their customers each day. Market has actually recognized the 5 stocks that cover analysts are silently murmuring to their clients to get now before the more comprehensive market catches on … and also Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” ranking amongst experts, top-rated analysts believe these five stocks are better gets.